bioRxiv (Cold Spring Harbor Laboratory)
March 24, 2026
Kenneth Shinozuka, Mattia Rosso, Anna Chaiken et al.
1 citation
Abstract Post-traumatic stress disorder (PTSD) is a debilitating condition that affects millions of veterans. A recent observational study in 30 veterans showed that a single dose of the atypical psychedelic ibogaine can be highly effective at treating PTSD up to twelve months later. Although a prior study demonstrated that ibogaine transiently alters electroencephalography (EEG) power in...
Journal of psychopharmacology (Oxford, England)
May 1, 2024
Thomas Knuijver, Rob Ter Heine, Arnt Schellekens et al.
15 citations
Ibogaine is a hallucinogenic drug that may be used to treat opioid use disorder (OUD). The relationships between pharmacokinetics (PKs) of ibogaine and its metabolites and their clinical effects on side effects and opioid withdrawal severity are unknown. We aimed to study these relationships in patients with OUD undergoing detoxification supported by ibogaine. The study was performed in 14...
Addiction (Abingdon, England)
2022
Thomas Knuijver, Arnt Schellekens, Maarten Belgers et al.
49 citations
Ibogaine is an indole alkaloid used in rituals of the African Bwiti tribe. It is also used in non-medical settings to treat addiction. However, ibogaine has been linked to several deaths, mainly due to cardiac events called torsades des pointes preceded by QTc prolongation as well as other safety concerns. This study aimed to evaluate the cardiac, cerebellar and psychomimetic safety of ibogaine...
Translational Psychiatry
May 31, 2016
Maarten Belgers, M Leenaars, Judith R. Homberg et al.
64 citations
Ibogaine is a naturally occurring substance which has been increasingly used in the lay-scene to reduce craving and relapse in patients with substance use disorders (SUDs). Although human clinical trials on the safety and efficacy of ibogaine are lacking, animal studies do support the efficacy of ibogaine. In this systematic review and meta-analysis (MA), we summarise these animal findings,...
European Psychiatry
March 1, 2016
Arnt Schellekens, Toon Van Oosteren, Thomas Knuijver et al.
1 citation
Background The use of the hallucinogen ibogaine as an anti-addiction agent has been described in several case reports, dating back to the eighties. The anti-addiction properties of ibogaine have been confirmed in a large body of animal work. Ibogaine has been shown to be effective in reducing withdrawal severity and substance use for a variety of substances, including cocaine and opiates....